The Cleo Roberts Center for Clinical Research, Banner Sun Health Research Institute, 10515 West Santa Fe Drive, Sun City, AZ, 85351, USA.
Drugs Aging. 2013 Oct;30(10):783-92. doi: 10.1007/s40266-013-0108-6.
To date, symptomatic medications prevail as the mainstay of treatment options for Alzheimer's disease (AD). There have been tremendous investments made to increase the numbers of drugs approved and the targets engaged, in an effort to alter the disease course or pathophysiology of AD. Unfortunately, almost all studies have not met expectations and no new drug (beyond medical foods) has been approved for the treatment of AD in the last decade. This review is a comparison of novel AD therapies in the late phases of clinical testing, including recent high-profile clinical failures, and agents in development with relatively unexplored mechanisms of action, with a focus on their potential as therapeutic agents and their proposed advantages over the treatments currently in use.
迄今为止，对症药物仍然是治疗阿尔茨海默病 (AD) 的主要选择。为了改变 AD 的病程或病理生理学，人们投入了大量资金来增加已批准药物的数量和作用靶点。不幸的是，几乎所有研究都没有达到预期效果，在过去十年中，没有一种新药（除了医用食品）被批准用于 AD 的治疗。本综述比较了处于临床测试后期的新型 AD 疗法，包括最近备受瞩目的临床失败案例，以及作用机制相对未知的研发药物，重点关注它们作为治疗药物的潜力及其相对于目前使用的治疗方法的优势。
